Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

How Dandelion Health’s multimodal dataset promises to shed light on GLP-1 research

By Brian Buntz | May 16, 2024

Dandelion HealthDandelion Health, the maker of a real-world data and clinical AI platform, has launched the first multimodal real-world clinical dataset focused on uncovering insights and opportunities related to GLP-1 receptor agonist drugs. The company describes the GLP-1 data library as “the first multimodal real-world clinical dataset” related to GLP-1 receptor agonists.

The library is sourced from Dandelion’s consortium of non-academic medical center health system partners spanning diverse geographic regions, including Sanford Health (a rural Midwest system), Sharp HealthCare (an urban California system) and Texas Health Resources (operating in cities and suburbs across the Southwest).

The multimodal aspect of the data sets it apart from many traditional healthcare datasets. Elliott Green, CEO and cofounder of the firm, pointed out, “80-90% of all healthcare data generated is imaging and waveforms — 12-lead ECGs, CTs, MRIs, X-rays, inpatient telemetry.” Historically, such information has not been deeply mined for insights. “Dandelion’s approach involves obtaining raw biological data that is typically only available through clinical trials.”

Amassing a research library for GLP-1 receptor agonists

Elliott Green

Elliott Green

While GLP-1 receptor agonists remain a relatively new class of drugs, interest in them has reached a fevered pitch in recent years given their potential to help manage obesity. This interest surge has led to a demand for more comprehensive data on the long-term effects of these medications, as well as their potential for other chronic diseases, given the core influence metabolism has on an array of diseases.

Uniting millions of patient journeys in data

With GLP-1s, Dandelion has curated data including millions of longitudinal patient journeys. Consequently, healthcare organizations armed with that data “can effectively answer many questions about how the drugs have potentially affected a specific condition, population, etc.,” Green said.

One example of Dandelion’s capabilities is using ECG data to predict cardiac event risk pre- and post-GLP-1 treatment in specific patient subgroups. Dandelion’s data has subsets of patients taking a GLP-1 that captures the before and after effects. This includes patients who had ECGs before GLP-1 therapy and then data from patients who had undergone the therapy.

Green noted that the available biological data allows for comparisons, even in the absence of lab tests or documented effects. “An ECG is 30,000 data points in 10 seconds,” Green said. Take that and incorporate data on co-morbidities and other patient info, and researchers can start to understand whether the medication class appears to reduce cardiac event risk for males, say, aged 30-45. Or whether it works better in one demographic versus another.

Iteratively redefining scale and depth

The scale of Dandelion’s dataset is already substantial, but it is growing rapidly. “By the end of this year with five health systems, we’ll have around 18–20 million patients,” Green said. “The larger sample size and variety of sub-cohorts in our dataset could provide deeper dosing insights compared to traditional clinical trials.” This represents an advantage over typical clinical trials, which might enroll only 1,500 to 5,000 people in a Phase 3 study. In contrast, millions of patients could be on a drug in the real world, depending on its indications and popularity. “It’s crazy we’re not doing more with that real-world data once the drug is out in the market,” Green said.

Real-world data has the potential to surface new treatment indications faster than traditional clinical research, Green noted. “Historically, you’d run 10, 20, 30, 40, 50 clinical trials to prove out those secondary impacts,” he said. But the data is constantly emerging.

Potentially broadening the scope of GLP-1 indications

Growing data availability and rising sophistication of healthcare organizations points to potentially faster, more efficient treatment indication discovery and tailored patient applications. “We can see it with the right data, and that data lives in health systems, it’s just not been accessible,” Green said.

GLP-1 indications beyond diabetes and obesity could increase in the coming years in areas such as neurodegenerative diseases and cardiology. “If you’d have said five years ago you have a drug that will help diabetes, massive weight loss, and potentially Parkinson’s or Alzheimer’s, people would think that’s crazy,” Green said. “But that’s what we’re dealing with now.” An approach to identifying these new indications lies in combining GLP-1 data with comprehensive patient data, especially from before and after patients began GLP-1 therapy. By analyzing this data, researchers can identify relationships between GLP-1 use and a spectrum of health markers, such as changes in brain plaques on MRI or head CT scans for neurological issues, or changes in ECG readings and cardiac events. This approach allows researchers to pinpoint promising areas for further investigation and drug discovery. “You start to see the correlation across so many things,” Green said. “You get a sense of where to hunt.”


Filed Under: Drug Discovery, machine learning and AI, Metabolic disease/endicrinology
Tagged With: cardiology, clinical AI, drug discovery, GLP-1 receptor agonists, neurodegenerative diseases, precision medicine, real-world data
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE